{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-24-000096","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.102580+00:00","generated_at":"2026-05-30T05:23:09.790645+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxcyte reports Q3 net loss $103M; cash $3.27B after $1.4B follow-on","bullets":["Net loss of $103.1M for Q3 2024 vs $92.7M in Q3 2023.","Cash, equivalents and investments $3,273M as of Sep 30, 2024, up from $1,243M at Dec 31, 2023.","VAX-31 Phase 1/2 topline positive: met non-inferiority vs PCV20 for all 20 shared serotypes at middle/high doses.","VAX-31 selected for Phase 3 adult program; pivotal non-inferiority study initiation expected by mid-2025.","VAX-24 infant Phase 2 primary series topline data expected by end of Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-24-000096","json":"https://secwatch.observer/filing/0001649094-24-000096.json","markdown":"https://secwatch.observer/filing/0001649094-24-000096.md","text":"https://secwatch.observer/filing/0001649094-24-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909424000096/0001649094-24-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909424000096/pcvx-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:23:09.790645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}